Besides, due to the activation of RPS6KB1 in Xp11.2 tRCC, Trilaciclib, an FDA-approved CDK5 inhibitor, was expected to become a potential therapeutic drug (36). This evidence concerns the gene RPS6KB1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.